中性粒细胞胞外陷阱
医学
抗磷脂综合征
抗血栓
狼疮抗凝剂
活化蛋白C抗性
血栓形成
免疫学
蛋白质C
内科学
血栓性
胃肠病学
作者
Thomas Foret,Virginie Dufrost,Lucie Salomon du Mont,Patricia Costa,Cécile Lakomy,Jeremy Lagrange,Patrick Lacolley,Véronique Regnault,Stéphane Zuily,Denis Wahl
出处
期刊:Rheumatology
[Oxford University Press]
日期:2021-11-16
被引量:1
标识
DOI:10.1093/rheumatology/keab853
摘要
In antiphospholipid syndrome (APS), precise evaluation of thrombotic risk is a major challenge. Different players, such as activated protein C (APC) resistance or neutrophil extracellular traps (NETs), contribute to the risk of thrombosis. Nevertheless, no study has investigated the interaction between these actors. The main objective of this study was to investigate the relation between NETs and APC resistance.We designed a cross-sectional study including APS/antiphospholipid antibodies (aPL) patients and patients with autoimmune diseases (AID). We performed thrombin generation tests without and with APC to determine APC resistance. To evaluate circulating NETs, we measured plasma levels of myeloperoxidase-DNA complexes and cell-free DNA with ELISA.We recruited 117 patients with definite APS/aPL or AID. We found a positive correlation between NETs and APC resistance, in APS patients and specifically in patients with high thrombotic risk, displaying lupus anticoagulant (LA) or positivity of all 3 aPL tests (triple+), or anti-domain I IgG (aDI+). All these patient subgroups had increased NETs concentrations and APC resistance. As the risk profile for thrombosis increased, the relationship between NETs and APC resistance was stronger.We have shown that NETs participate in the hypercoagulable state of APS patients by contributing to APC resistance, in particular in high-risk patients. In these most at-risk patients, a targeted action on NETs could reduce APC resistance and constitute a new therapeutic approach in the treatment of APS patients in addition to antithrombotic therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI